The 29th Conference on Retroviruses and Opportunistic Infections (CROI), will be live for virtual participation only. February 12 to 16 will include the Opening Session, technical workshops, plenary presentations, interactive sessions, oral sessions, and poster presentations. NEW: February 22, 23, and 24, 2022, will include symposia with state-of-the-art talks and responses to audience questions.

The program begins each day at 8:30 AM Mountain Time US (Convert to Other Time Zones). For your convenience, use the Mark Your Calendar link to add all the live session times of the conference on your calendar.

To view the CROI 2022 Preliminary Program Guide with abstract titles, click here.

The printable CROI 2022 Schedule at a Glance is now available to download.

8:30 AM MT - 12:30 PM MT
SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

Widely considered the most informative and comprehensive session, this workshop highlights key presentations that will take place during CROI. Although the workshop is directed toward new investigators and trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows), all CROI attendees are encouraged to attend. Scholarship recipients are required to attend.

Moderators: Nicolas Chomont, Université de Montréal, and Serena S. Spudich, Yale University
  • ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2 – Theodora Hatziioannou, Rockefeller University, New York, NY, USA
  • ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY – Penny Moore, University of the Witwatersrand, Johannesburg, South Africa
  • ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC – Carlos del Rio, Emory University, Atlanta, GA, USA
  • ADVANCES IN BIOMEDICAL PREVENTION OF HIV – Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • ADVANCES IN HIV CURE WITH CLINICAL PERSPECTIVES – Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA
8:30 AM MT - 10:45 AM MT
OPENING SESSION

MARTIN DELANEY PRESENTATION

WE’RE STILL HERE: HIV, AGING, AND THE INVISIBLE GENERATION

Marc Thompson, PrEPster, London, UK

The Martin Delaney Presentation recognizes the important contributions of community advocacy and engagement to HIV/AIDS research.

BERNARD FIELDS LECTURE

VACCINE STRATEGIES FOR HIV-1 AND COVID-19

Dan H. Barouch, Beth Israel Deaconess Medical Center, Boston, MA, USA

The Bernard Fields Lecture recognizes a basic scientist for important and relevant contributions to the fields of virology and viral pathogenesis.

N’GALY-MANN LECTURE

HIV RESEARCH: GENERATING EVIDENCE TO ADVANCE PUBLIC HEALTH POLICIES IN BRAZIL

Beatriz Grinsztejn, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for important and relevant work in the fields of epidemiology or clinical research.

FIRESIDE CHAT WITH ROCHELLE WALENSKY

Moderator: Elaine J. Abrams

THE COVID-19 EPIDEMIC IN THE UNITED STATES: A DISCUSSION WITH DR ROCHELLE WALENSKY

Rochelle P. Walensky, Centers for Disease Control and Prevention, Atlanta, GA, USA

A special moderated discussion with Dr Walensky, the 19th Director of the Centers for Disease Control and Prevention, will focus on the US response to the COVID-19 pandemic.

11:00 AM MT - 1:00 PM MT
CONCURRENT TECHNICAL WORKSHOPS

FRONTIERS IN LABORATORY TECHNOLOGIES

Moderators: Galit Alter, Ragon Institute of MGH, MIT and Harvard and Frank Kirchhoff, Ulm University Medical Center
  • POPULATION LEVEL VIRAL SEQUENCING – Tulio de Oliveira, University of KwaZulu-Natal, Durban, South Africa
  • DEEP MUTATIONAL SCANNING TO INTERPRET VIRAL EVOLUTION – Jesse Bloom, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • AI-INSPIRED MONOCLONAL THERAPEUTIC ANTIBODY DESIGN – Regina Barzilay, Massachusetts Institute of Technology, Cambridge, MA, USA
  • SINGLE-CELL PROTEOMICS – Nikolai Slavov, Northeastern University, Boston, MA, USA

CASE-BASED LIVER WORKSHOP

Moderators: David Wyles, Denver Health Medical Center and Marina B. Klein, McGill University Health Centre
  • LIVER STEATOSIS IN PERSONS LIVING WITH HIV – Maud Lemoine, Imperial College London, London, UK
  • GETTING HEPATITIS C AGAIN – Maria Prins, Public Health Service of Amsterdam, Amsterdam, Netherlands
  • CONTROVERSIES IN HEPATITIS B – Chloe L. Thio, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • THE ORIGINAL DELTA VIRUS OR D LIKE THE DEVIL – Markus Cornberg, Medizinische Hochschule Hannover, Hannover, Germany

CLINICAL TRIAL DESIGN AND ANALYSIS

Moderators: Susan P. Buchbinder, San Francisco Department of Public Health and Richard E. Chaisson The Johns Hopkins University
  • STUDYING COVID TREATMENT OUTCOMES: WHY DISPARATE RESULTS? – Eric J. Rubin, New England Journal of Medicine, Boston, MA, USA
  • ANALYSIS APPROACHES TO CORRELATES OF VACCINE EFFICACY – Peter Gilbert, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • ASSESSING VACCINE EFFICACY IN THE REAL WORLD – Sheena G. Sullivan, University of Melbourne, Melbourne, Australia
8:30 AM MT - 9:30 AM MT
MONDAY PLENARY SESSION

HIV NONHUMAN PRIMATE MODELS FOR STUDIES OF VIRUS PATHOGENESIS, PERSISTENCE, AND CURE

Michaela Müller-Trutwin, Institut Pasteur, Paris, France

CHILDREN EXPOSED TO HIV, BUT UNINFECTED: EVIDENCE FOR ACTION

Andrew J. Prendergast, Queen Mary University of London, London, United Kingdom

9:45 AM MT - 11:45 AM MT
ORAL ABSTRACT SESSIONS
  • TARGETS AND BARRIERS TO VIRAL INFECTION
  • MATERNAL AND CHILD HEALTH: NEW INSIGHTS INTO HEPATITIS, SARS-CoV-2, AND HIV
  • MALIGNANCIES AND COMORBIDITIES: AN INCREASING BURDEN
  • EVOLVING EPIDEMIOLOGY OF HIV AND SARS-CoV-2
12:00 PM MT - 1:00 PM MT
CONCURRENT INTERACTIVE SESSIONS

VIRAL SURVIVAL STRATEGIES IN THE FACE OF HOST IMMUNE RESPONSES: IMPLICATIONS FOR VACCINES

Moderators: Guido Silvestri, Emory University and Douglas D. Richman, University of California San Diego
  • UNIQUE CHALLENGES OF VACCINATING DURING A PANDEMIC – John P. Moore, Weill Cornell Medical College, New York, NY, USA
  • HPV VACCINE: A SUCCESSFUL MODEL OF VACCINE-INDUCED MUCOSAL ANTIVIRAL IMMUNE RESPONSE – Margaret Stanley, University of Cambridge, Cambridge, UK
  • FLU VACCINES: THE GLASS HALF-FULL – Florian Krammer, Columbia University, New York, NY, USA
  • HERPES VIRUSES: VIRUSES THAT EVADE VACCINE-INDUCED HOST-IMMUNE RESPONSES – Betsy Herold, Albert Einstein College of Medicine, New York, NY, USA
  • HIV-1: THE ULTIMATE CHALLENGE FOR VACCINE DEVELOPMENT – Alexandra Trkola, University of Zurich, Zurich, Switzerland

COVID-19 TREATMENT: CONSENSUS AND CONTROVERSIES

Case presentations with a discussion by the expert panel and questions from the audience.

Moderators: Annie Luetkemeyer, University of California San Francisco, San Francisco, CA, USA, and Rajesh T. Gandhi, Massachusetts General Hospital, Boston, MA, USA

Panelists:

  • Ghady Haidar, University of Pittsburgh, Pittsburgh, PA, USA
  • Laura E. Riley, Weill Cornell Medicine, New York, NY, USA
  • David Lye, National Centre for Infectious Diseases, Singapore
  • Sandra Wagner-Cardoso, Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil

(COVID-19) VACCINE MANDATES: THE PAST, THE PRESENT, AND THE WAY FORWARD

Presentations followed by a panel discussion and questions from the audience.

Moderators: Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, and Carlos Del Rio, Emory University, Atlanta, GA, USA
  • VACCINE MANDATES: HISTORY IN THE UNITED STATES AND OTHER COUNTRIES – Ruth Macklin, Albert Einstein College of Medicine, New York, NY, USA
  • VACCINE HESITANCY AMONG MEMBERS OF RACIAL AND ETHNIC MINORITY GROUPS – Matifadza Hlatshwayo Davis, City of St Louis Department of Health, Saint Louis, MO, USA
  • LEGAL AND POLITICAL ISSUES RELATED TO VACCINE MANDATES IN THE US, AND SOLUTIONS FOR OVERCOMING THEM – Lawrence O. Gostin, Georgetown University, Washington, DC, USA
1:15 PM MT - 1:55 PM MT
Networking Sessions For New Investigators
2:00 PM MT - 3:30 PM MT
Live Chat Sessions With Poster Presenters

Discussion with poster presenters is available on the conference platform throughout the CROI. Attendees are especially encouraged to engage with poster presenters during the designated live chat sessions.

Poster-A01 INFECTION AND ENVELOPE
Poster-B01 NONHUMAN PRIMATE MODELS OF HIV INFECTION
Poster-B02 SARS-CoV-2 PATHOGENESIS
Poster-B04 HIV TRANSMISSION
Poster-D01 HIV VACCINES
Poster-D02 SARS-CoV-2 VACCINES
Poster-D08 HIV IMMUNOLOGY: NK CELLS AND CYTOKINES
Poster-D10 EBOLAVIRUS VACCINES
Poster-E03 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND
Poster-E04 CONTROLLERS AND POST-TREATMENT CONTROLLERS
Poster-F03 HIV, SIV, AND SARS-CoV-2 NEUROPATHOGENESIS MODELING
Poster-F04 BLOOD AND CSF BIOMARKERS OF BRAIN INTEGRITY AND FUNCTION
Poster-G01 WHAT’S NEW IN PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS
Poster-H05 NOVEL AGENTS: INTRIGUING RESULTS
Poster-I01 PROFILING THE SENSITIVITY OF HIV TO NEUTRALIZING ANTIBODIES IN VIVO
Poster-I02 IMPACT OF HIV MUTATIONS ON FITNESS, DRUG RESISTANCE, AND TREATMENT RESPONSE
Poster-J01 FATTY LIVER: NAFL, MAFL, AND NASH
Poster-K01 CANCER RISK, TREATMENT, AND EPIDEMIOLOGY
Poster-L01 RISK FACTOR AND INFLAMMATORY MEDIATORS OF CARDIOVASULAR DISEASE
Poster-M04 FRAILTY AND SLEEP DISTURBANCES
Poster-M05 BIOMARKERS AND COMORBIDITIES
Poster-N01 POSTACUTE SEQUELLAE OF SARS-CoV-2 INFECTION
Poster-O04 NOVEL INSIGHTS IN CRYPTOCOCCAL MENINGITIS EPIDEMIOLOGY, TREATMENT, AND OUTCOMES
Poster-O05 CMV AND FUNGAL OPPORTUNISTIC INFECTIONS
Poster-P03 EVOLVING INSIGHTS: MTCT RISK TO MATERNAL HEALTH
Poster-P04 NEW PERSPECTIVES ON THE HEALTH OF CHILDREN EXPOSED TO HIV IN UTERO
Poster-Q01 TIMING OF AND TESTING FOR HIV IN INFANTS, CHILDREN, AND YOUTH
Poster-Q04 COMORBIDITIES AND COMPLICATIONS OF HIV AND ART IN CHILDREN AND YOUTH
Poster-R04 HIV CLUSTERS AND OUTBREAKS
Poster-R06 HIV EPIDEMIOLOGY
Poster-T04 ADVANCES IN SARS-CoV-2 DIAGNOSTICS
Poster-V01 PrEP: SERVICES, COST-EFFECTIVENESS, BONE LOSS, AND ARV RESISTANCE
Poster-X01 SEXUAL AND REPRODUCTIVE HEALTH IN THE TIME OF COVID-19
Poster-Y07 HIV AND SURVIVAL
Poster-Y08 COVID-19 AND HIV
8:30 AM MT - 9:30 AM MT
TUESDAY PLENARY SESSION

NEW INSIGHTS INTO HIV RNA BIOLOGY

Michael Summers, University of Maryland Baltimore County, Baltimore, MD, USA

UNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE

Muge Cevik, University of St Andrews, St Andrews, UK

9:45 AM MT - 11:45 AM MT
ORAL ABSTRACT SESSIONS
  • HIV RESERVOIRS AND CURE STRATEGIES
  • TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HEPATITIS
  • HIV PREVENTION: FROM THE BENCH TO POPULATION
  • GLOBAL PERSPECTIVES ON HIV TESTING, TREATMENT, AND PREVENTION
  • SARS-CoV-2 ANTIVIRALS AND OUTCOMES
12:00 PM MT - 1:00 PM MT
CONCURRENT INTERACTIVE SESSIONS

LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND

Moderators: Galit Alter, Ragon Institute of MGH, MIT and Harvard and Karine Lacombe, Sorbonne Université

Presentations followed by a panel discussion and questions from the audience.

  • PUTTING LONG COVID IN CONTEXT – Steven G. Deeks, University of California San Francisco, San Francisco, CA, USA
  • THEMES IN NEUROLOGY – Avindra Nath, National Institutes of Health, Bethesda, MD, USA
  • THEMES IN VIROLOGY – Susan R. Weiss, University of Pennsylvania, Philadelphia, PA, USA
  • THEMES IN IMMUNOLOGY – Akiko Iwasaki, Yale University, New Haven, CT, USA

WHAT WILL IT TAKE TO INCREASE PEP AND PrEP USE FOR ADOLESCENT GIRLS AND YOUNG WOMEN AT RISK?

Moderators: Susan P. Buchbinder, San Francisco Department of Public Health and Moses R. Kamya, Makerere University College of Health Sciences

Presentations followed by a panel discussion and questions from the audience.

  • GLOBAL PrEP UPTAKE IN ADOLESCENT GIRLS AND YOUNG WOMEN – Rachel Baggaley, World Health Organization, Geneva, Switzerland
  • EXPERIENCE WITH OFFERING PEP ALONGSIDE PrEP – James Ayieko, Kenya Medical Research Institute, Nairobi, Kenya
  • PrEP IMPLEMENTATION IN ADOLESCENT GIRLS AND YOUNG WOMEN – Nicolette Naidoo, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
  • PrEP IMPLEMENTATION IN YOUNG SEX WORKERS IN ZIMBABWE – Primrose Matambanadzo, Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
1:15 PM MT - 1:55 PM MT
Networking Sessions for New Investigators
2:00 PM MT - 3:30 PM MT
Live Chat Sessions With Poster Presenters

Discussion with poster presenters is available on the conference platform throughout the CROI. Attendees are especially encouraged to engage with poster presenters during the designated live chat sessions.

Poster-A02 IMMUNE CELL INFECTION AND RESPONSES
Poster-B03 CORRELATES OF SARS-CoV-2 OUTCOMES
Poster-B05 HIV REPLICATION IN VIVO
Poster-D03 HIV IMMUNOLOGY: T CELLS
Poster-D09 SARS-CoV-2 IMMUNOLOGY: T CELLS, NK CELLS, AND CYTOKINES
Poster-E01 SINGLE-CELL ANALYSES OF HIV RESERVOIRS
Poster-E06 DYNAMICS OF HIV RESERVOIRS AND VIRAL REBOUND
Poster-F01 CNS RESERVOIRS, REGULATION, AND ESCAPE
Poster-F06 NEUROCOGNITION: PREDICTIONS, TRAJECTORIES, AND THERAPEUTICS
Poster-G02 HIV PREVENTION AND MUCOSAL COMPARTMENT PHARMACOLOGY
Poster-H01 CLINICAL TRIALS OF THERAPY FOR SARS-CoV-2: ANTIVIRALS AND IMMUNE MODIFIERS
Poster-H02 NEW ANTIVIRALS FOR SARS-CoV-2: ACTIVITY IN VITRO AND IN VIVO
Poster-I03 NEW TECHNOLOGIES TO DETECT HIV DRUG RESISTANCE
Poster-I04 TRANSMITTED HIV DRUG RESISTANCE
Poster-J02 HCV TREATMENT AND DISEASE
Poster-J03 HCV ELIMINATION AND CARE CASCADE
Poster-K02 CERVICAL CANCER AND ANAL CANCER: PREVALENCE AND SCREENING
Poster-K03 BASIC SCIENCE OF HPV, KSHV, AND HIV-ASSOCIATED LYMPHOMAS
Poster-L02 HYPERTENSION, HEART FAILURE, AND OTHER CARDIOVASCULAR DISEASE OUTCOMES
Poster-M03 OTHER COMORBIDITIES
Poster-N02 NEUROCOGNITIVE MANIFESTATIONS OF COVID-19
Poster-O02 PHARMACOLOGIC RELATIONSHIPS ASSOCIATED WITH TB DRUGS AND OUTCOMES
Poster-O03 TB EPIDEMIOLOGY, TREATMENT, AND IMPLEMENTATION SCIENCE
Poster-P01 COVID-19 IN MOTHERS AND THEIR CHILDREN
Poster-P02 HIV, ART, AND PREGNANCY OUTCOMES: EPIDEMIOLOGY AND MECHANISMS
Poster-Q02 EARLY TREATMENT AND HIV RESERVOIRS IN CHILDREN
Poster-Q06 ALL THINGS COVID-19 IN CHILDREN
Poster-R01 SARS-CoV-2 EPIDEMIOLOGY
Poster-R05 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION
Poster-T03 HIV DIAGNOSTICS
Poster-V02 PrEP IN ADOLESCENTS AND PREGNANT PEOPLE
Poster-V03 HIV PREVENTION: NALTREXONE, PEP, AND PrEP FOR TRANSGENDER PEOPLE
Poster-X03 THE PLOT THICKENS: SEXUAL AND REPRODUCTIVE HEALTH ISSUES IN PEOPLE WITH HIV
Poster-Y04 SUBSTANCE USE
Poster-Y05 HIV PREVENTION
Poster-Y06 MENTAL HEALTH AND STIGMA
8:30 AM MT - 9:30 AM MT
WEDNESDAY PLENARY SESSION

NEW ANTIRETROVIRALS AND THE FUTURE OF HIV TREATMENT AND PREVENTION

Chloe Orkin, Queen Mary University of London, London, United Kingdom

PAST AND FUTURE OF HIV VACCINES

Mark Feinberg, International AIDS Vaccine Initiative (IAVI), Amsterdam, Netherlands

9:45 AM MT - 11:45 AM MT
ORAL ABSTRACT SESSIONS
  • IMMUNE RESPONSES TO HIV AND SARS-CoV-2 IN TREATMENT, PREVENTION, AND PATHOGENESIS
  • CROSSING THE CNS BORDER: HIV, SIV, AND SARS-CoV-2
  • HIV ANTIVIRALS AND OUTCOMES
  • SHIFTING PARADIGMS IN HIV TESTING
12:00 PM MT - 1:00 PM MT
CONCURRENT INTERACTIVE SESSIONS

CHIMERIC ANTIGEN RECEPTORS (CARs): WHAT’S NEXT?

Moderators: Richard A. Koup, National Institute of Allergy and Infectious Diseases, and James Hoxie, University of Pennsylvania

Presentations followed by a panel discussion and questions from the audience.

  • NEW AND IMPROVED T CELL CARs FOR HIV ERADICATION OR CONTROL – James L. Riley, University of Pennsylvania, Philadelphia, PA, USA
  • GENERATING CAR T CELLS IN VIVO – Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, Seattle, USA
  • NATURAL KILLER CELL CARs: NEW APPROACHES TO CURE LEUKEMIA AND LYMPHOMA – Katy Rezvani, University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • STIMULATING CARs WITH mRNA VACCINES – Benjamin Rengstl, BioNTech, Mainz, Germany

HIV CONTROVERSIES: CASE-BASED APPROACH TO PATIENTS WHO ARE TREATMENT OR PREVENTION EXPERIENCED

Case presentations with discussion by the expert panel and questions from the audience.

Panelists

  • Joseph J. Eron, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Mina C. Hosseinipour, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Hermione Lyall, Imperial College Healthcare NHS Trust, London, UK
  • Natella Rakhmanina, Children’s National Hospital, Washington, DC, USA
  • Annemarie Wensing, University Medical Center Utrecht, Utrecht, Netherlands
  • Timothy Wilkin, Weill Cornell Medicine, New York, NY, USA

IMPACT OF VIRAL LOAD IN TRANSMISSION AND DISEASE PROGRESSION OF SARS-CoV-2 INFECTION

Moderators: Jean-Michel Molina, University of Paris and Monica Gandhi, University of California San Francisco

Presentations followed by a panel discussion and questions from the audience.

  • ROLE OF VARIANTS AND VIRAL LOAD IN SARS-CoV-2 TRANSMISSION – Arnaud Fontanet, Institut Pasteur, Paris, France
  • IS SARS-CoV-2 VIRAL LOAD ASSOCIATED WITH DISEASE PROGRESSION AND RESPONSE TO TREATMENT? – Matthew Spinelli, University of California San Francisco, San Francisco, CA, USA
  • ARE NEW SARS-CoV-2 VARIANTS ASSOCIATED WITH MORE SEVERE DISEASE? – Fiona Havers, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • VIRAL LOAD KINETICS IN PARTIALLY OR FULLY VACCINATED INDIVIDUALS INFECTED WITH SARS-CoV-2 – Annelies Wilder-Smith, London School of Hygiene & Tropical Medicine, London, UK
2:00 PM MT - 3:30 PM MT
Live Chat Sessions With Poster Presenters

Discussion with poster presenters is available on the conference platform throughout the CROI. Attendees are especially encouraged to engage with poster presenters during the designated live chat sessions.

Poster-A03 VIRUS REPLICATION AND HOST FACTORS
Poster-B06 OUTCOMES OF HIV INFECTION
Poster-B07 HIV INFECTION AND INFLAMMATION
Poster-D04 SARS-CoV-2 IMMUNOLOGY: B CELLS AND ANTIBODIES
Poster-D05 HIV IMMUNE THERAPY
Poster-D06 SARS-CoV-2 VACCINE RESPONSES IN SPECIAL POPULATIONS
Poster-D07 SARS-CoV-2 IMMUNE THERAPY
Poster-E02 MECHANISMS OF HIV LATENCY: MAINTENANCE AND REVERSAL
Poster-E05 IMMUNE PRESSURES ON THE HIV RESERVOIR
Poster-F02 ART: EFFICACY, SWITCHES, AND TOXICITY
Poster-F05 NEUROIMAGING PROFILING AND OUTCOMES
Poster-G03 FROM FORMULATION TO DRUG EXPOSURE TO ADHERENCE: IMPORTANT PRINCIPLES IN PHARMACOLOGY
Poster-H03 ANTIRETROVIRAL THERAPY IN EXPERIENCED PATIENTS: SUSTAIN OR REGAIN SUPPRESSION
Poster-H04 FIRST-LINE THERAPY, LOW-LEVEL VIREMIA, AND ADHERENCE
Poster-J04 HBV EPIDEMIOLOGY, TREATMENT, AND PREVENTION
Poster-J05 EXPRESSION AND PATHOGENESIS OF LIVER DISEASE
Poster-K04 KAPOSI SARCOMA TREATMENT AND HTLV
Poster-M01 WEIGHT GAIN AND ADIPOSE TISSUE BIOLOGY
Poster-M02 METABOLIC COMPLICATIONS
Poster-N03 COVID-19: MISCELLANEOUS CLINICAL AND THERAPEUTIC ISSUES
Poster-O01 NOVEL MYCOBACTERIAL DIAGNOSTICS AND BIOMARKERS
Poster-P05 HIV INFECTION AND PREVENTION IN PREGNANCY
Poster-Q03 REAL-WORLD OUTCOMES IN PEDIATRICS
Poster-Q05 PK, SAFETY, AND ACCEPTABILITY OF NEW AGENTS FOR CHILDREN AND YOUTH
Poster-R02 FACTORS ASSOCIATED WITH SURVIVAL IN PEOPLE WITH HIV
Poster-R03 HIV CARE OUTCOMES
Poster-T01 DETECTING RECENT INFECTIONS
Poster-T02 UNDERSTANDING AND STRENGTHENING HIV DIAGNOSIS AND MONITORING
Poster-T05 APPLYING SARS-CoV-2 TESTS IN PRACTICE
Poster-V04 EARLY PHASE STUDIES OF HIV VACCINES, bNAbs, AND NEXT-GENERATION PrEP
Poster-V05 COVID-19 TRACING, VACCINES, AND EFFECT OF TDF ON COVID-19 SEVERITY
Poster-X02 THE TANGLED WEB: SEXUAL AND REPRODUCTIVE HEALTH AND HIV RISK
Poster-Y01 VIRAL LOAD MEASUREMENT AND SUPPRESSION
Poster-Y02 HIV INCIDENCE, TESTING, AND LINKAGE
Poster-Y03 RETENTION AND VIRAL SUPPRESSION
8:30 AM MT - 10:00 AM MT
SYMPOSIUM

GETTING INTO SHAPE: A DEEPER LOOK AT VIRAL MATURATION

Moderators: Theodora Hatziioannou, The Rockefeller University, and Frank Kirchhoff Ulm University Medical Center
  • HIV-1 MATURATION – NEW VIEWS OF AN EXTRAORDINARY METAMORPHOSIS – John Briggs, Max Planck Institute of Biochemistry, Martinsried, Germany
  • NEW ROLE FOR INTEGRASE IN VIRAL MATURATION – Sebla B. Kutluay, Washington University in St Louis, Saint Louis, MO, USA
  • STRUCTURE, ASSEMBLY, AND FUNCTIONAL ROLES OF THE INTASOME IN HIV REPLICATION – Dmitry Lyumkis, Salk Institute for Biological Sciences, La Jolla, CA, USA
10:15 AM MT - 11:45 AM MT
SYMPOSIUM

INFANT POSTNATAL PROPHYLAXIS: WHY BOTHER?

Moderators: Sharon Nachman, State University of New York at Stony Brook and Tim R. Cressey, Chiang Mai University
  • SETTING THE STAGE: POSTNATAL PROPHYLAXIS TO REDUCE NEW PEDIATRIC INFECTIONS – Claire Thorne, University College London, London, UK
  • ANTIRETROVIRALS FOR PREVENTION: FROM ADULTS TO BABIES – Martina Penazzato, World Health Organization, Geneva, Switzerland
  • SPEED DIALING NEONATES TO THE IDEAL POSTNATAL PROPHYLAXIS REGIMEN – Adrie Bekker, Stellenbosch University, Cape Town, South Africa
12:00 PM MT - 1:30 PM MT
SYMPOSIUM

BRINGING CHOICE TO HIV PREVENTION

Moderators: Sharon L. Hillier, University of Pittsburgh Medical Center and James A. McIntyre, Anova Health Institute
  • PREPARING FOR THE PLATE OF PREVENTION OPTIONS: HOW CAN WE DELIVER? – Hyman Scott, San Francisco Department of Public Health, San Francisco, CA, USA
  • BUILDING BACK BETTER: PUBLIC HEALTH SYSTEMS, PUBLIC TRUST, AND THE PrEP PIPELINE – Kenyon Farrow, PrEP4ALL, New York, NY, USA
  • APPLYING LESSONS ON EFFICACY AND AUTONOMY FROM CONTRACEPTION TO PrEP – Dominika Seidman, University of California San Francisco, San Francisco, CA, USA
8:30 AM MT - 10:00 AM MT
SYMPOSIUM

THE HIV RESERVOIR: CREATION, SELECTION, MAINTENANCE, AND REVERSAL

Moderators: Katharine J. Bar, University of Pennsylvania, and Nicolas Chomont, Université de Montréal
  • THE HIV-1 PROVIRAL LANDSCAPE: WHAT HAVE WE LEARNED? – Sarah Palmer, The Westmead Institute for Medical Research, Westmead, Australia
  • ROLE OF SELECTION PRESSURES AND IMMUNE RESPONSES IN SHAPING THE PERSISTENT RESERVOIR – Francesco R. Simonetti, Johns Hopkins University, Baltimore, MD, USA
  • NOVEL IMMUNOTHERAPY-BASED CURE INTERVENTIONS – Mirko Paiardini, Emory University, Atlanta, GA, USA
10:15 AM MT - 11:45 AM MT
SYMPOSIUM

TUBERCULOSIS: NEW STRATEGIES IN THE TREATMENT OF THE WORLD’S OLDEST EPIDEMIC

Moderators: Constance A. Benson, University of California San Diego and William J. Burman, Denver Public Health
  • TREATMENT SHORTENING FOR DRUG-SUSCEPTIBLE TB: WHERE ARE WE AND WHAT’S NEXT? – Susan Dorman, Medical University of South Carolina, Charleston, SC, USA
  • A NEW ERA FOR TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS – David Moore, London School of Hygiene & Tropical Medicine, London, UK
  • THE PROMISE OF NEW DRUGS AND LONG-ACTING INJECTABLES FOR TB TREATMENT AND PREVENTION – Eric L. Nuermberger, Johns Hopkins University, Baltimore, MD, USA
12:00 PM MT - 1:30 PM MT
SYMPOSIUM

SEXUALLY TRANSMITTED INFECTIONS: REVERSING THE TIDE

Moderators: Connie L. Celum, University of Washington and Jonathan Mermin, Centers for Disease Control and Prevention
  • THE STATE OF STI EPIDEMICS AND RESPONSE IN THE UNITED STATES – Leandro Mena, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • CURRENT AND FUTURE RESEARCH IN STI VACCINES – Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
  • SEXUALLY TRANSMITTED INFECTIONS PROPHYLAXIS, IS THIS THE ANSWER? – Elizabeth A. Bukusi, Kenya Medical Research Institute, Nairobi, Kenya
8:30 AM MT - 10:00 AM MT
SYMPOSIUM

IMMUNE PROTECTION IN THE FIELD: RAISING THE STAKES

Moderators: Penny Moore, University of the Witwatersrand and Huldrych F. Günthard, University Hospital Zurich
  • LESSONS LEARNED FROM THE AMP TRIAL: IS THE GLASS HALF FULL? – Carolyn Williamson, University of Cape Town, Cape Town, South Africa
  • PUSHING THE ENVELOPE: mRNA VACCINES FOR COVID-19, HIV, AND OTHER PATHOGENS – Drew Weissman, University of Pennsylvania, Philadelphia, PA, USA
  • JUMP-STARTED IMMUNE RESPONSE: NOW, HOW TO TEACH BREADTH? – William R. Schief, Scripps Research Institute, La Jolla, CA, USA
10:15 AM MT - 11:45 AM MT
SYMPOSIUM

HIV AND AGING

Moderator: Peter W. Hunt, University of California San Francisco
  • CLINICAL EPIDEMIOLOGY OF AGING AND COMORBIDITY WITH HIV INFECTION: A GLOBAL PERSPECTIVE – Mark Siedner, Harvard Medical School, Boston, MA, USA
  • POTENTIAL BIOLOGIC MECHANISMS OF AGING IN HIV – Nicholas Funderburg, The Ohio State University, Columbus, OH, USA
  • INTEGRATING FRAILTY AND FUNCTIONAL OUTCOMES INTO CLINICAL TRIALS – Kristine Erlandson, University of Colorado, Denver, CO, USA
  • Panelist – Jules Levin, National AIDS Treatment Advocacy Project, New York, NY, USA
  • Panelist – Venita Ray, Positive Women’s Network, Oakland, CA, USA
12:00 PM MT - 1:30 PM MT
SYMPOSIUM

HIV PREVENTION IN SPECIAL POPULATIONS

Moderators: Jessica E. Justman, Columbia University and Raphael J. Landovitz, University of California Los Angeles
  • A COMPREHENSIVE APPROACH TO HIV PREVENTION IN PEOPLE WHO USE SUBSTANCES – Adam W. Carrico, University of Miami, Miami, FL, USA
  • TAILORING HIV PREVENTION STRATEGIES FOR THE UNIQUE NEEDS OF TRANSGENDER AND NONBINARY PEOPLE – Sari L. Reisner, Brigham and Women’s Hospital, Boston, MA, USA
  • HIV PREVENTION APPROACHES TAILORED TO INDIVIDUALS ENGAGED IN SEX WORK – Frances Cowan, Liverpool School of Tropical Medicine, Harare, Zimbabwe
Saturday, February 12, 2022
8:30 AM MT - 12:30 PM MT
SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

Widely considered the most informative and comprehensive session, this workshop highlights key presentations that will take place during CROI. Although the workshop is directed toward new investigators and trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows), all CROI attendees are encouraged to attend. Scholarship recipients are required to attend.

Moderators: Nicolas Chomont, Université de Montréal, and Serena S. Spudich, Yale University
  • ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2 – Theodora Hatziioannou, Rockefeller University, New York, NY, USA
  • ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY – Penny Moore, University of the Witwatersrand, Johannesburg, South Africa
  • ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC – Carlos del Rio, Emory University, Atlanta, GA, USA
  • ADVANCES IN BIOMEDICAL PREVENTION OF HIV – Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • ADVANCES IN HIV CURE WITH CLINICAL PERSPECTIVES – Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA
Sunday, February 13, 2022
8:30 AM MT - 10:45 AM MT
OPENING SESSION

MARTIN DELANEY PRESENTATION

WE’RE STILL HERE: HIV, AGING, AND THE INVISIBLE GENERATION

Marc Thompson, PrEPster, London, UK

The Martin Delaney Presentation recognizes the important contributions of community advocacy and engagement to HIV/AIDS research.

BERNARD FIELDS LECTURE

VACCINE STRATEGIES FOR HIV-1 AND COVID-19

Dan H. Barouch, Beth Israel Deaconess Medical Center, Boston, MA, USA

The Bernard Fields Lecture recognizes a basic scientist for important and relevant contributions to the fields of virology and viral pathogenesis.

N’GALY-MANN LECTURE

HIV RESEARCH: GENERATING EVIDENCE TO ADVANCE PUBLIC HEALTH POLICIES IN BRAZIL

Beatriz Grinsztejn, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for important and relevant work in the fields of epidemiology or clinical research.

FIRESIDE CHAT WITH ROCHELLE WALENSKY

Moderator: Elaine J. Abrams

THE COVID-19 EPIDEMIC IN THE UNITED STATES: A DISCUSSION WITH DR ROCHELLE WALENSKY

Rochelle P. Walensky, Centers for Disease Control and Prevention, Atlanta, GA, USA

A special moderated discussion with Dr Walensky, the 19th Director of the Centers for Disease Control and Prevention, will focus on the US response to the COVID-19 pandemic.

11:00 AM MT - 1:00 PM MT
CONCURRENT TECHNICAL WORKSHOPS

FRONTIERS IN LABORATORY TECHNOLOGIES

Moderators: Galit Alter, Ragon Institute of MGH, MIT and Harvard and Frank Kirchhoff, Ulm University Medical Center
  • POPULATION LEVEL VIRAL SEQUENCING – Tulio de Oliveira, University of KwaZulu-Natal, Durban, South Africa
  • DEEP MUTATIONAL SCANNING TO INTERPRET VIRAL EVOLUTION – Jesse Bloom, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • AI-INSPIRED MONOCLONAL THERAPEUTIC ANTIBODY DESIGN – Regina Barzilay, Massachusetts Institute of Technology, Cambridge, MA, USA
  • SINGLE-CELL PROTEOMICS – Nikolai Slavov, Northeastern University, Boston, MA, USA

CASE-BASED LIVER WORKSHOP

Moderators: David Wyles, Denver Health Medical Center and Marina B. Klein, McGill University Health Centre
  • LIVER STEATOSIS IN PERSONS LIVING WITH HIV – Maud Lemoine, Imperial College London, London, UK
  • GETTING HEPATITIS C AGAIN – Maria Prins, Public Health Service of Amsterdam, Amsterdam, Netherlands
  • CONTROVERSIES IN HEPATITIS B – Chloe L. Thio, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • THE ORIGINAL DELTA VIRUS OR D LIKE THE DEVIL – Markus Cornberg, Medizinische Hochschule Hannover, Hannover, Germany

CLINICAL TRIAL DESIGN AND ANALYSIS

Moderators: Susan P. Buchbinder, San Francisco Department of Public Health and Richard E. Chaisson The Johns Hopkins University
  • STUDYING COVID TREATMENT OUTCOMES: WHY DISPARATE RESULTS? – Eric J. Rubin, New England Journal of Medicine, Boston, MA, USA
  • ANALYSIS APPROACHES TO CORRELATES OF VACCINE EFFICACY – Peter Gilbert, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • ASSESSING VACCINE EFFICACY IN THE REAL WORLD – Sheena G. Sullivan, University of Melbourne, Melbourne, Australia
Monday, February 14, 2022
8:30 AM MT - 9:30 AM MT
MONDAY PLENARY SESSION

HIV NONHUMAN PRIMATE MODELS FOR STUDIES OF VIRUS PATHOGENESIS, PERSISTENCE, AND CURE

Michaela Müller-Trutwin, Institut Pasteur, Paris, France

CHILDREN EXPOSED TO HIV, BUT UNINFECTED: EVIDENCE FOR ACTION

Andrew J. Prendergast, Queen Mary University of London, London, United Kingdom

9:45 AM MT - 11:45 AM MT
ORAL ABSTRACT SESSIONS
  • TARGETS AND BARRIERS TO VIRAL INFECTION
  • MATERNAL AND CHILD HEALTH: NEW INSIGHTS INTO HEPATITIS, SARS-CoV-2, AND HIV
  • MALIGNANCIES AND COMORBIDITIES: AN INCREASING BURDEN
  • EVOLVING EPIDEMIOLOGY OF HIV AND SARS-CoV-2
12:00 PM MT - 1:00 PM MT
CONCURRENT INTERACTIVE SESSIONS

VIRAL SURVIVAL STRATEGIES IN THE FACE OF HOST IMMUNE RESPONSES: IMPLICATIONS FOR VACCINES

Moderators: Guido Silvestri, Emory University and Douglas D. Richman, University of California San Diego
  • UNIQUE CHALLENGES OF VACCINATING DURING A PANDEMIC – John P. Moore, Weill Cornell Medical College, New York, NY, USA
  • HPV VACCINE: A SUCCESSFUL MODEL OF VACCINE-INDUCED MUCOSAL ANTIVIRAL IMMUNE RESPONSE – Margaret Stanley, University of Cambridge, Cambridge, UK
  • FLU VACCINES: THE GLASS HALF-FULL – Florian Krammer, Columbia University, New York, NY, USA
  • HERPES VIRUSES: VIRUSES THAT EVADE VACCINE-INDUCED HOST-IMMUNE RESPONSES – Betsy Herold, Albert Einstein College of Medicine, New York, NY, USA
  • HIV-1: THE ULTIMATE CHALLENGE FOR VACCINE DEVELOPMENT – Alexandra Trkola, University of Zurich, Zurich, Switzerland

COVID-19 TREATMENT: CONSENSUS AND CONTROVERSIES

Case presentations with a discussion by the expert panel and questions from the audience.

Moderators: Annie Luetkemeyer, University of California San Francisco, San Francisco, CA, USA, and Rajesh T. Gandhi, Massachusetts General Hospital, Boston, MA, USA

Panelists:

  • Ghady Haidar, University of Pittsburgh, Pittsburgh, PA, USA
  • Laura E. Riley, Weill Cornell Medicine, New York, NY, USA
  • David Lye, National Centre for Infectious Diseases, Singapore
  • Sandra Wagner-Cardoso, Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil

(COVID-19) VACCINE MANDATES: THE PAST, THE PRESENT, AND THE WAY FORWARD

Presentations followed by a panel discussion and questions from the audience.

Moderators: Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, and Carlos Del Rio, Emory University, Atlanta, GA, USA
  • VACCINE MANDATES: HISTORY IN THE UNITED STATES AND OTHER COUNTRIES – Ruth Macklin, Albert Einstein College of Medicine, New York, NY, USA
  • VACCINE HESITANCY AMONG MEMBERS OF RACIAL AND ETHNIC MINORITY GROUPS – Matifadza Hlatshwayo Davis, City of St Louis Department of Health, Saint Louis, MO, USA
  • LEGAL AND POLITICAL ISSUES RELATED TO VACCINE MANDATES IN THE US, AND SOLUTIONS FOR OVERCOMING THEM – Lawrence O. Gostin, Georgetown University, Washington, DC, USA
1:15 PM MT - 1:55 PM MT
Networking Sessions For New Investigators
2:00 PM MT - 3:30 PM MT
Live Chat Sessions With Poster Presenters

Discussion with poster presenters is available on the conference platform throughout the CROI. Attendees are especially encouraged to engage with poster presenters during the designated live chat sessions.

Poster-A01 INFECTION AND ENVELOPE
Poster-B01 NONHUMAN PRIMATE MODELS OF HIV INFECTION
Poster-B02 SARS-CoV-2 PATHOGENESIS
Poster-B04 HIV TRANSMISSION
Poster-D01 HIV VACCINES
Poster-D02 SARS-CoV-2 VACCINES
Poster-D08 HIV IMMUNOLOGY: NK CELLS AND CYTOKINES
Poster-D10 EBOLAVIRUS VACCINES
Poster-E03 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND
Poster-E04 CONTROLLERS AND POST-TREATMENT CONTROLLERS
Poster-F03 HIV, SIV, AND SARS-CoV-2 NEUROPATHOGENESIS MODELING
Poster-F04 BLOOD AND CSF BIOMARKERS OF BRAIN INTEGRITY AND FUNCTION
Poster-G01 WHAT’S NEW IN PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS
Poster-H05 NOVEL AGENTS: INTRIGUING RESULTS
Poster-I01 PROFILING THE SENSITIVITY OF HIV TO NEUTRALIZING ANTIBODIES IN VIVO
Poster-I02 IMPACT OF HIV MUTATIONS ON FITNESS, DRUG RESISTANCE, AND TREATMENT RESPONSE
Poster-J01 FATTY LIVER: NAFL, MAFL, AND NASH
Poster-K01 CANCER RISK, TREATMENT, AND EPIDEMIOLOGY
Poster-L01 RISK FACTOR AND INFLAMMATORY MEDIATORS OF CARDIOVASULAR DISEASE
Poster-M04 FRAILTY AND SLEEP DISTURBANCES
Poster-M05 BIOMARKERS AND COMORBIDITIES
Poster-N01 POSTACUTE SEQUELLAE OF SARS-CoV-2 INFECTION
Poster-O04 NOVEL INSIGHTS IN CRYPTOCOCCAL MENINGITIS EPIDEMIOLOGY, TREATMENT, AND OUTCOMES
Poster-O05 CMV AND FUNGAL OPPORTUNISTIC INFECTIONS
Poster-P03 EVOLVING INSIGHTS: MTCT RISK TO MATERNAL HEALTH
Poster-P04 NEW PERSPECTIVES ON THE HEALTH OF CHILDREN EXPOSED TO HIV IN UTERO
Poster-Q01 TIMING OF AND TESTING FOR HIV IN INFANTS, CHILDREN, AND YOUTH
Poster-Q04 COMORBIDITIES AND COMPLICATIONS OF HIV AND ART IN CHILDREN AND YOUTH
Poster-R04 HIV CLUSTERS AND OUTBREAKS
Poster-R06 HIV EPIDEMIOLOGY
Poster-T04 ADVANCES IN SARS-CoV-2 DIAGNOSTICS
Poster-V01 PrEP: SERVICES, COST-EFFECTIVENESS, BONE LOSS, AND ARV RESISTANCE
Poster-X01 SEXUAL AND REPRODUCTIVE HEALTH IN THE TIME OF COVID-19
Poster-Y07 HIV AND SURVIVAL
Poster-Y08 COVID-19 AND HIV
Tuesday, February 15, 2022
8:30 AM MT - 9:30 AM MT
TUESDAY PLENARY SESSION

NEW INSIGHTS INTO HIV RNA BIOLOGY

Michael Summers, University of Maryland Baltimore County, Baltimore, MD, USA

UNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE

Muge Cevik, University of St Andrews, St Andrews, UK

9:45 AM MT - 11:45 AM MT
ORAL ABSTRACT SESSIONS
  • HIV RESERVOIRS AND CURE STRATEGIES
  • TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HEPATITIS
  • HIV PREVENTION: FROM THE BENCH TO POPULATION
  • GLOBAL PERSPECTIVES ON HIV TESTING, TREATMENT, AND PREVENTION
  • SARS-CoV-2 ANTIVIRALS AND OUTCOMES
12:00 PM MT - 1:00 PM MT
CONCURRENT INTERACTIVE SESSIONS

LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND

Moderators: Galit Alter, Ragon Institute of MGH, MIT and Harvard and Karine Lacombe, Sorbonne Université

Presentations followed by a panel discussion and questions from the audience.

  • PUTTING LONG COVID IN CONTEXT – Steven G. Deeks, University of California San Francisco, San Francisco, CA, USA
  • THEMES IN NEUROLOGY – Avindra Nath, National Institutes of Health, Bethesda, MD, USA
  • THEMES IN VIROLOGY – Susan R. Weiss, University of Pennsylvania, Philadelphia, PA, USA
  • THEMES IN IMMUNOLOGY – Akiko Iwasaki, Yale University, New Haven, CT, USA

WHAT WILL IT TAKE TO INCREASE PEP AND PrEP USE FOR ADOLESCENT GIRLS AND YOUNG WOMEN AT RISK?

Moderators: Susan P. Buchbinder, San Francisco Department of Public Health and Moses R. Kamya, Makerere University College of Health Sciences

Presentations followed by a panel discussion and questions from the audience.

  • GLOBAL PrEP UPTAKE IN ADOLESCENT GIRLS AND YOUNG WOMEN – Rachel Baggaley, World Health Organization, Geneva, Switzerland
  • EXPERIENCE WITH OFFERING PEP ALONGSIDE PrEP – James Ayieko, Kenya Medical Research Institute, Nairobi, Kenya
  • PrEP IMPLEMENTATION IN ADOLESCENT GIRLS AND YOUNG WOMEN – Nicolette Naidoo, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
  • PrEP IMPLEMENTATION IN YOUNG SEX WORKERS IN ZIMBABWE – Primrose Matambanadzo, Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
1:15 PM MT - 1:55 PM MT
Networking Sessions for New Investigators
2:00 PM MT - 3:30 PM MT
Live Chat Sessions With Poster Presenters

Discussion with poster presenters is available on the conference platform throughout the CROI. Attendees are especially encouraged to engage with poster presenters during the designated live chat sessions.

Poster-A02 IMMUNE CELL INFECTION AND RESPONSES
Poster-B03 CORRELATES OF SARS-CoV-2 OUTCOMES
Poster-B05 HIV REPLICATION IN VIVO
Poster-D03 HIV IMMUNOLOGY: T CELLS
Poster-D09 SARS-CoV-2 IMMUNOLOGY: T CELLS, NK CELLS, AND CYTOKINES
Poster-E01 SINGLE-CELL ANALYSES OF HIV RESERVOIRS
Poster-E06 DYNAMICS OF HIV RESERVOIRS AND VIRAL REBOUND
Poster-F01 CNS RESERVOIRS, REGULATION, AND ESCAPE
Poster-F06 NEUROCOGNITION: PREDICTIONS, TRAJECTORIES, AND THERAPEUTICS
Poster-G02 HIV PREVENTION AND MUCOSAL COMPARTMENT PHARMACOLOGY
Poster-H01 CLINICAL TRIALS OF THERAPY FOR SARS-CoV-2: ANTIVIRALS AND IMMUNE MODIFIERS
Poster-H02 NEW ANTIVIRALS FOR SARS-CoV-2: ACTIVITY IN VITRO AND IN VIVO
Poster-I03 NEW TECHNOLOGIES TO DETECT HIV DRUG RESISTANCE
Poster-I04 TRANSMITTED HIV DRUG RESISTANCE
Poster-J02 HCV TREATMENT AND DISEASE
Poster-J03 HCV ELIMINATION AND CARE CASCADE
Poster-K02 CERVICAL CANCER AND ANAL CANCER: PREVALENCE AND SCREENING
Poster-K03 BASIC SCIENCE OF HPV, KSHV, AND HIV-ASSOCIATED LYMPHOMAS
Poster-L02 HYPERTENSION, HEART FAILURE, AND OTHER CARDIOVASCULAR DISEASE OUTCOMES
Poster-M03 OTHER COMORBIDITIES
Poster-N02 NEUROCOGNITIVE MANIFESTATIONS OF COVID-19
Poster-O02 PHARMACOLOGIC RELATIONSHIPS ASSOCIATED WITH TB DRUGS AND OUTCOMES
Poster-O03 TB EPIDEMIOLOGY, TREATMENT, AND IMPLEMENTATION SCIENCE
Poster-P01 COVID-19 IN MOTHERS AND THEIR CHILDREN
Poster-P02 HIV, ART, AND PREGNANCY OUTCOMES: EPIDEMIOLOGY AND MECHANISMS
Poster-Q02 EARLY TREATMENT AND HIV RESERVOIRS IN CHILDREN
Poster-Q06 ALL THINGS COVID-19 IN CHILDREN
Poster-R01 SARS-CoV-2 EPIDEMIOLOGY
Poster-R05 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION
Poster-T03 HIV DIAGNOSTICS
Poster-V02 PrEP IN ADOLESCENTS AND PREGNANT PEOPLE
Poster-V03 HIV PREVENTION: NALTREXONE, PEP, AND PrEP FOR TRANSGENDER PEOPLE
Poster-X03 THE PLOT THICKENS: SEXUAL AND REPRODUCTIVE HEALTH ISSUES IN PEOPLE WITH HIV
Poster-Y04 SUBSTANCE USE
Poster-Y05 HIV PREVENTION
Poster-Y06 MENTAL HEALTH AND STIGMA
Wednesday, February 16, 2022
8:30 AM MT - 9:30 AM MT
WEDNESDAY PLENARY SESSION

NEW ANTIRETROVIRALS AND THE FUTURE OF HIV TREATMENT AND PREVENTION

Chloe Orkin, Queen Mary University of London, London, United Kingdom

PAST AND FUTURE OF HIV VACCINES

Mark Feinberg, International AIDS Vaccine Initiative (IAVI), Amsterdam, Netherlands

9:45 AM MT - 11:45 AM MT
ORAL ABSTRACT SESSIONS
  • IMMUNE RESPONSES TO HIV AND SARS-CoV-2 IN TREATMENT, PREVENTION, AND PATHOGENESIS
  • CROSSING THE CNS BORDER: HIV, SIV, AND SARS-CoV-2
  • HIV ANTIVIRALS AND OUTCOMES
  • SHIFTING PARADIGMS IN HIV TESTING
12:00 PM MT - 1:00 PM MT
CONCURRENT INTERACTIVE SESSIONS

CHIMERIC ANTIGEN RECEPTORS (CARs): WHAT’S NEXT?

Moderators: Richard A. Koup, National Institute of Allergy and Infectious Diseases, and James Hoxie, University of Pennsylvania

Presentations followed by a panel discussion and questions from the audience.

  • NEW AND IMPROVED T CELL CARs FOR HIV ERADICATION OR CONTROL – James L. Riley, University of Pennsylvania, Philadelphia, PA, USA
  • GENERATING CAR T CELLS IN VIVO – Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, Seattle, USA
  • NATURAL KILLER CELL CARs: NEW APPROACHES TO CURE LEUKEMIA AND LYMPHOMA – Katy Rezvani, University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • STIMULATING CARs WITH mRNA VACCINES – Benjamin Rengstl, BioNTech, Mainz, Germany

HIV CONTROVERSIES: CASE-BASED APPROACH TO PATIENTS WHO ARE TREATMENT OR PREVENTION EXPERIENCED

Case presentations with discussion by the expert panel and questions from the audience.

Panelists

  • Joseph J. Eron, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Mina C. Hosseinipour, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Hermione Lyall, Imperial College Healthcare NHS Trust, London, UK
  • Natella Rakhmanina, Children’s National Hospital, Washington, DC, USA
  • Annemarie Wensing, University Medical Center Utrecht, Utrecht, Netherlands
  • Timothy Wilkin, Weill Cornell Medicine, New York, NY, USA

IMPACT OF VIRAL LOAD IN TRANSMISSION AND DISEASE PROGRESSION OF SARS-CoV-2 INFECTION

Moderators: Jean-Michel Molina, University of Paris and Monica Gandhi, University of California San Francisco

Presentations followed by a panel discussion and questions from the audience.

  • ROLE OF VARIANTS AND VIRAL LOAD IN SARS-CoV-2 TRANSMISSION – Arnaud Fontanet, Institut Pasteur, Paris, France
  • IS SARS-CoV-2 VIRAL LOAD ASSOCIATED WITH DISEASE PROGRESSION AND RESPONSE TO TREATMENT? – Matthew Spinelli, University of California San Francisco, San Francisco, CA, USA
  • ARE NEW SARS-CoV-2 VARIANTS ASSOCIATED WITH MORE SEVERE DISEASE? – Fiona Havers, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • VIRAL LOAD KINETICS IN PARTIALLY OR FULLY VACCINATED INDIVIDUALS INFECTED WITH SARS-CoV-2 – Annelies Wilder-Smith, London School of Hygiene & Tropical Medicine, London, UK
2:00 PM MT - 3:30 PM MT
Live Chat Sessions With Poster Presenters

Discussion with poster presenters is available on the conference platform throughout the CROI. Attendees are especially encouraged to engage with poster presenters during the designated live chat sessions.

Poster-A03 VIRUS REPLICATION AND HOST FACTORS
Poster-B06 OUTCOMES OF HIV INFECTION
Poster-B07 HIV INFECTION AND INFLAMMATION
Poster-D04 SARS-CoV-2 IMMUNOLOGY: B CELLS AND ANTIBODIES
Poster-D05 HIV IMMUNE THERAPY
Poster-D06 SARS-CoV-2 VACCINE RESPONSES IN SPECIAL POPULATIONS
Poster-D07 SARS-CoV-2 IMMUNE THERAPY
Poster-E02 MECHANISMS OF HIV LATENCY: MAINTENANCE AND REVERSAL
Poster-E05 IMMUNE PRESSURES ON THE HIV RESERVOIR
Poster-F02 ART: EFFICACY, SWITCHES, AND TOXICITY
Poster-F05 NEUROIMAGING PROFILING AND OUTCOMES
Poster-G03 FROM FORMULATION TO DRUG EXPOSURE TO ADHERENCE: IMPORTANT PRINCIPLES IN PHARMACOLOGY
Poster-H03 ANTIRETROVIRAL THERAPY IN EXPERIENCED PATIENTS: SUSTAIN OR REGAIN SUPPRESSION
Poster-H04 FIRST-LINE THERAPY, LOW-LEVEL VIREMIA, AND ADHERENCE
Poster-J04 HBV EPIDEMIOLOGY, TREATMENT, AND PREVENTION
Poster-J05 EXPRESSION AND PATHOGENESIS OF LIVER DISEASE
Poster-K04 KAPOSI SARCOMA TREATMENT AND HTLV
Poster-M01 WEIGHT GAIN AND ADIPOSE TISSUE BIOLOGY
Poster-M02 METABOLIC COMPLICATIONS
Poster-N03 COVID-19: MISCELLANEOUS CLINICAL AND THERAPEUTIC ISSUES
Poster-O01 NOVEL MYCOBACTERIAL DIAGNOSTICS AND BIOMARKERS
Poster-P05 HIV INFECTION AND PREVENTION IN PREGNANCY
Poster-Q03 REAL-WORLD OUTCOMES IN PEDIATRICS
Poster-Q05 PK, SAFETY, AND ACCEPTABILITY OF NEW AGENTS FOR CHILDREN AND YOUTH
Poster-R02 FACTORS ASSOCIATED WITH SURVIVAL IN PEOPLE WITH HIV
Poster-R03 HIV CARE OUTCOMES
Poster-T01 DETECTING RECENT INFECTIONS
Poster-T02 UNDERSTANDING AND STRENGTHENING HIV DIAGNOSIS AND MONITORING
Poster-T05 APPLYING SARS-CoV-2 TESTS IN PRACTICE
Poster-V04 EARLY PHASE STUDIES OF HIV VACCINES, bNAbs, AND NEXT-GENERATION PrEP
Poster-V05 COVID-19 TRACING, VACCINES, AND EFFECT OF TDF ON COVID-19 SEVERITY
Poster-X02 THE TANGLED WEB: SEXUAL AND REPRODUCTIVE HEALTH AND HIV RISK
Poster-Y01 VIRAL LOAD MEASUREMENT AND SUPPRESSION
Poster-Y02 HIV INCIDENCE, TESTING, AND LINKAGE
Poster-Y03 RETENTION AND VIRAL SUPPRESSION
Tuesday, February 22, 2022
8:30 AM MT - 10:00 AM MT
SYMPOSIUM

GETTING INTO SHAPE: A DEEPER LOOK AT VIRAL MATURATION

Moderators: Theodora Hatziioannou, The Rockefeller University, and Frank Kirchhoff Ulm University Medical Center
  • HIV-1 MATURATION – NEW VIEWS OF AN EXTRAORDINARY METAMORPHOSIS – John Briggs, Max Planck Institute of Biochemistry, Martinsried, Germany
  • NEW ROLE FOR INTEGRASE IN VIRAL MATURATION – Sebla B. Kutluay, Washington University in St Louis, Saint Louis, MO, USA
  • STRUCTURE, ASSEMBLY, AND FUNCTIONAL ROLES OF THE INTASOME IN HIV REPLICATION – Dmitry Lyumkis, Salk Institute for Biological Sciences, La Jolla, CA, USA
10:15 AM MT - 11:45 AM MT
SYMPOSIUM

INFANT POSTNATAL PROPHYLAXIS: WHY BOTHER?

Moderators: Sharon Nachman, State University of New York at Stony Brook and Tim R. Cressey, Chiang Mai University
  • SETTING THE STAGE: POSTNATAL PROPHYLAXIS TO REDUCE NEW PEDIATRIC INFECTIONS – Claire Thorne, University College London, London, UK
  • ANTIRETROVIRALS FOR PREVENTION: FROM ADULTS TO BABIES – Martina Penazzato, World Health Organization, Geneva, Switzerland
  • SPEED DIALING NEONATES TO THE IDEAL POSTNATAL PROPHYLAXIS REGIMEN – Adrie Bekker, Stellenbosch University, Cape Town, South Africa
12:00 PM MT - 1:30 PM MT
SYMPOSIUM

BRINGING CHOICE TO HIV PREVENTION

Moderators: Sharon L. Hillier, University of Pittsburgh Medical Center and James A. McIntyre, Anova Health Institute
  • PREPARING FOR THE PLATE OF PREVENTION OPTIONS: HOW CAN WE DELIVER? – Hyman Scott, San Francisco Department of Public Health, San Francisco, CA, USA
  • BUILDING BACK BETTER: PUBLIC HEALTH SYSTEMS, PUBLIC TRUST, AND THE PrEP PIPELINE – Kenyon Farrow, PrEP4ALL, New York, NY, USA
  • APPLYING LESSONS ON EFFICACY AND AUTONOMY FROM CONTRACEPTION TO PrEP – Dominika Seidman, University of California San Francisco, San Francisco, CA, USA
Wednesday, February 23, 2022
8:30 AM MT - 10:00 AM MT
SYMPOSIUM

THE HIV RESERVOIR: CREATION, SELECTION, MAINTENANCE, AND REVERSAL

Moderators: Katharine J. Bar, University of Pennsylvania, and Nicolas Chomont, Université de Montréal
  • THE HIV-1 PROVIRAL LANDSCAPE: WHAT HAVE WE LEARNED? – Sarah Palmer, The Westmead Institute for Medical Research, Westmead, Australia
  • ROLE OF SELECTION PRESSURES AND IMMUNE RESPONSES IN SHAPING THE PERSISTENT RESERVOIR – Francesco R. Simonetti, Johns Hopkins University, Baltimore, MD, USA
  • NOVEL IMMUNOTHERAPY-BASED CURE INTERVENTIONS – Mirko Paiardini, Emory University, Atlanta, GA, USA
10:15 AM MT - 11:45 AM MT
SYMPOSIUM

TUBERCULOSIS: NEW STRATEGIES IN THE TREATMENT OF THE WORLD’S OLDEST EPIDEMIC

Moderators: Constance A. Benson, University of California San Diego and William J. Burman, Denver Public Health
  • TREATMENT SHORTENING FOR DRUG-SUSCEPTIBLE TB: WHERE ARE WE AND WHAT’S NEXT? – Susan Dorman, Medical University of South Carolina, Charleston, SC, USA
  • A NEW ERA FOR TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS – David Moore, London School of Hygiene & Tropical Medicine, London, UK
  • THE PROMISE OF NEW DRUGS AND LONG-ACTING INJECTABLES FOR TB TREATMENT AND PREVENTION – Eric L. Nuermberger, Johns Hopkins University, Baltimore, MD, USA
12:00 PM MT - 1:30 PM MT
SYMPOSIUM

SEXUALLY TRANSMITTED INFECTIONS: REVERSING THE TIDE

Moderators: Connie L. Celum, University of Washington and Jonathan Mermin, Centers for Disease Control and Prevention
  • THE STATE OF STI EPIDEMICS AND RESPONSE IN THE UNITED STATES – Leandro Mena, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • CURRENT AND FUTURE RESEARCH IN STI VACCINES – Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
  • SEXUALLY TRANSMITTED INFECTIONS PROPHYLAXIS, IS THIS THE ANSWER? – Elizabeth A. Bukusi, Kenya Medical Research Institute, Nairobi, Kenya
Thursday, February 24, 2022
8:30 AM MT - 10:00 AM MT
SYMPOSIUM

IMMUNE PROTECTION IN THE FIELD: RAISING THE STAKES

Moderators: Penny Moore, University of the Witwatersrand and Huldrych F. Günthard, University Hospital Zurich
  • LESSONS LEARNED FROM THE AMP TRIAL: IS THE GLASS HALF FULL? – Carolyn Williamson, University of Cape Town, Cape Town, South Africa
  • PUSHING THE ENVELOPE: mRNA VACCINES FOR COVID-19, HIV, AND OTHER PATHOGENS – Drew Weissman, University of Pennsylvania, Philadelphia, PA, USA
  • JUMP-STARTED IMMUNE RESPONSE: NOW, HOW TO TEACH BREADTH? – William R. Schief, Scripps Research Institute, La Jolla, CA, USA
10:15 AM MT - 11:45 AM MT
SYMPOSIUM

HIV AND AGING

Moderator: Peter W. Hunt, University of California San Francisco
  • CLINICAL EPIDEMIOLOGY OF AGING AND COMORBIDITY WITH HIV INFECTION: A GLOBAL PERSPECTIVE – Mark Siedner, Harvard Medical School, Boston, MA, USA
  • POTENTIAL BIOLOGIC MECHANISMS OF AGING IN HIV – Nicholas Funderburg, The Ohio State University, Columbus, OH, USA
  • INTEGRATING FRAILTY AND FUNCTIONAL OUTCOMES INTO CLINICAL TRIALS – Kristine Erlandson, University of Colorado, Denver, CO, USA
  • Panelist – Jules Levin, National AIDS Treatment Advocacy Project, New York, NY, USA
  • Panelist – Venita Ray, Positive Women’s Network, Oakland, CA, USA
12:00 PM MT - 1:30 PM MT
SYMPOSIUM

HIV PREVENTION IN SPECIAL POPULATIONS

Moderators: Jessica E. Justman, Columbia University and Raphael J. Landovitz, University of California Los Angeles
  • A COMPREHENSIVE APPROACH TO HIV PREVENTION IN PEOPLE WHO USE SUBSTANCES – Adam W. Carrico, University of Miami, Miami, FL, USA
  • TAILORING HIV PREVENTION STRATEGIES FOR THE UNIQUE NEEDS OF TRANSGENDER AND NONBINARY PEOPLE – Sari L. Reisner, Brigham and Women’s Hospital, Boston, MA, USA
  • HIV PREVENTION APPROACHES TAILORED TO INDIVIDUALS ENGAGED IN SEX WORK – Frances Cowan, Liverpool School of Tropical Medicine, Harare, Zimbabwe